Journal
NEUROENDOCRINOLOGY
Volume 109, Issue 1, Pages 57-69Publisher
KARGER
DOI: 10.1159/000497205
Keywords
Aggressiveness; Dopamine receptor; Dopamine agonists; Preclinical models
Categories
Funding
- Junta de Andalucia [CTS-1406, BIO-0139]
- ISCIII-FIS
- European Union (ERDF/ESF, Investing in Your Future) [CP15/00156, PI17/02287]
- CIBER (an initiative of the Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain)
- Deutsche Forschungsgemeinschaft (DFG) within the CRC/Transregio [205/1]
Ask authors/readers for more resources
Prolactin-secreting tumors (prolactinomas) represent the most common pituitary tumor type, accounting for 47-66% of functional pituitary tumors. Prolactinomas are usually benign and controllable tumors as they express abundant levels of dopamine type 2 receptor (D2), and can be treated with dopaminergic drugs, effectively reducing prolactin levels and tumor volume. However, a proportion of prolactinomas exhibit aggressive features (including invasiveness, relevant growth despite adequate dopamine agonist treatment, and recurrence potential) and few may exhibit metastasizing potential (carcinomas). In this context, the clinical, pathological, and molecular definitions of malignant and aggressive prolactinomas remain to be clearly defined, as primary prolactin-secreting carcinomas are similar to aggressive adenomas until the presence of metastases is detected. Indeed, standard molecular and histological analyses do not reflect differences between carcinomas and adenomas at a first glance and have limitations in prediction of the aggressive progression of prolactinomas, wherein the causes underlying the aggressive behavior remain unknown. Herein we present a comprehensive, multidisciplinary review of the most relevant epidemiological, clinical, pathological, genetic, biochemical, and molecular aspects of aggressive and malignant prolactinomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available